Literature DB >> 2349952

Complex alleles of the acid beta-glucosidase gene in Gaucher disease.

T Latham1, G A Grabowski, B D Theophilus, F I Smith.   

Abstract

Gaucher disease is inherited in an autosomal recessive manner and is the most prevalent lysosomal storage disease. Gaucher disease has marked phenotypic variation and molecular heterogeneity, and seven point mutations in the acid beta-glucosidase (beta-Glc) gene have been identified. By means of sequence-specific oligonucleotides (SSO), mutation 6433C has been detected homozygously in neuronopathic type 2 (acute) and type 3 (subacute) patients, as well as in children with severe visceral involvement who are apparently free of neuronopathic disease. To investigate the molecular basis for this puzzling finding, amplified beta-Glc cDNAs from 6433C homozygous type 2 and type 3 Gaucher disease patients were cloned and sequenced. The Swedish type 3 Gaucher disease patient was truly homozygous for alleles only containing the 6433C mutation. In comparison, the type 2 patient contained a singly mutated 6433C allele and a "complex" allele with multiple discrete point mutations (6433C, 6468C, and 6482C). Each of the mutations in the complex allele also was present in the beta-Glc pseudogene. SSO hybridization of 6433C homozygotes revealed that both type 2 patients contained additional mutations in one allele, whereas the 6433C alone was detected in both type 3 and in young severe type 1 Gaucher disease patients. These results suggest that the presence of the complex allele influences the severity of neuronopathic disease in 6433C homozygotes and reveal the central role played by the pseudogene in the formation of mutant alleles of the beta-Glc gene. Analysis of additional cDNA clones also identified two new alleles in a type 3 patient, emphasizing the molecular heterogeneity of neuronopathic Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2349952      PMCID: PMC1683763     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

2.  Population study of chronic Gaucher's disease.

Authors:  K Fried
Journal:  Isr J Med Sci       Date:  1973 Sep-Oct

3.  Supercoil sequencing: a fast and simple method for sequencing plasmid DNA.

Authors:  E Y Chen; P H Seeburg
Journal:  DNA       Date:  1985-04

4.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

5.  Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene.

Authors:  B D Theophilus; T Latham; G A Grabowski; F I Smith
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

6.  Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.

Authors:  E I Ginns; R O Brady; S Pirruccello; C Moore; S Sorrell; F S Furbish; G J Murray; J Tager; J A Barranger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

7.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

8.  Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease.

Authors:  E Beutler; W Kuhl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

9.  Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.

Authors:  G A Grabowski; J Goldblatt; T Dinur; J Kruse; L Svennerholm; S Gatt; R J Desnick
Journal:  Am J Med Genet       Date:  1985-07

10.  Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site.

Authors:  T Dinur; K M Osiecki; G Legler; S Gatt; R J Desnick; G A Grabowski
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

View more
  32 in total

1.  Mutation analysis in 46 British and Irish patients with Gaucher's disease.

Authors:  C E Hatton; A Cooper; C Whitehouse; J E Wraith
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

2.  The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.

Authors:  E Sidransky; N Tayebi; B K Stubblefield; W Eliason; A Klineburgess; G P Pizzolato; J N Cox; J Porta; A Bottani; C D DeLozier-Blanchet
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

3.  Three prevalent mutations in a patient with phenylalanine hydroxylase deficiency: implications for diagnosis and genetic counselling.

Authors:  P Guldberg; H L Levy; K F Henriksen; F Guttler
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

4.  A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients.

Authors:  H Kawame; Y Eto
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

5.  Clinical and molecular characteristics of Japanese Gaucher disease.

Authors:  Y Eto; H Ida
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

6.  Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II.

Authors:  E Natt; K Kida; M Odievre; M Di Rocco; G Scherer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

7.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

8.  Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients.

Authors:  M Horowitz; G Tzuri; N Eyal; A Berebi; E H Kolodny; R O Brady; N W Barton; A Abrahamov; A Zimran
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

9.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

Review 10.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.